TNXP - トニックス・ファ―マシュ―ティカルズ (Tonix Pharmaceuticals Holding Corp.)

TNXPのニュース

   Is Tonix Pharmaceuticals About To Breakdown?  2021/04/20 13:41:50 Benzinga
There is a good chance Tonix Pharmaceuticals (NASDAQ: TNXP ) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically. Many investors like to place their orders at nice round levels and that’s the case here. When TNXP fell to $1 in early March, a rally followed. But that may … Full story available on Benzinga.com
   Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact  2021/04/19 11:52:04 Benzinga
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19. The financial details of the deal were … Full story available on Benzinga.com
   worth buying post Earnings results? NASDAQ:TNXP NASDAQ:CUE NASDAQ:SMTC NASDAQ:HHR and #Covid-19 (#Coronavirus) impact  2021/03/20 19:14:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia  2021/03/19 11:58:01 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. which is paid by Tonix Pharmaceuticals Holding Corp. to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) announced late last year positive results for the first of two pivotal Phase 3 studies of its lead fibromyalgia drug candidate, TNX-102 SL. The company reported that the results from its Phase 3 RELIEF study revealed TNX-102 SL provided statistically significant daily pain reduction over placebo while also being well-tolerated by participants in the study. “We are delighted with the results of our first positive Phase 3 study of TNX-102 SL for the management of fibromyalgia,” said Tonix Pharmaceuticals CEO, Dr. Seth Lederman. “RELIEF is the first of two studies that are required for approval by the U.S.
   NewtoTheStreet's Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin - Stocks News Feed  2021/02/13 20:39:00 Stocks News Feed
NEW YORK, NY / ACCESSWIRE / February 13, 2021 / New To The Street will broadcast Show 151 Sunday 930AM EST on NEWSMAX T.V., and on FOX Business Monday evening 1030PM PST. The show will feature Doctor Seth Lederman President and co-founder Tonix Pharma, a research driven biotechnology company. Tonix is working on a 1… Read More »NewtoTheStreet’s Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin
   Is Tonix Pharmaceuticals About To Breakdown?  2021/04/20 13:41:50 Benzinga
There is a good chance Tonix Pharmaceuticals (NASDAQ: TNXP ) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically. Many investors like to place their orders at nice round levels and that’s the case here. When TNXP fell to $1 in early March, a rally followed. But that may … Full story available on Benzinga.com
   Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact  2021/04/19 11:52:04 Benzinga
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19. The financial details of the deal were … Full story available on Benzinga.com
   worth buying post Earnings results? NASDAQ:TNXP NASDAQ:CUE NASDAQ:SMTC NASDAQ:HHR and #Covid-19 (#Coronavirus) impact  2021/03/20 19:14:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia  2021/03/19 11:58:01 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. which is paid by Tonix Pharmaceuticals Holding Corp. to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) announced late last year positive results for the first of two pivotal Phase 3 studies of its lead fibromyalgia drug candidate, TNX-102 SL. The company reported that the results from its Phase 3 RELIEF study revealed TNX-102 SL provided statistically significant daily pain reduction over placebo while also being well-tolerated by participants in the study. “We are delighted with the results of our first positive Phase 3 study of TNX-102 SL for the management of fibromyalgia,” said Tonix Pharmaceuticals CEO, Dr. Seth Lederman. “RELIEF is the first of two studies that are required for approval by the U.S.
   NewtoTheStreet's Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin - Stocks News Feed  2021/02/13 20:39:00 Stocks News Feed
NEW YORK, NY / ACCESSWIRE / February 13, 2021 / New To The Street will broadcast Show 151 Sunday 930AM EST on NEWSMAX T.V., and on FOX Business Monday evening 1030PM PST. The show will feature Doctor Seth Lederman President and co-founder Tonix Pharma, a research driven biotechnology company. Tonix is working on a 1… Read More »NewtoTheStreet’s Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin
   Is Tonix Pharmaceuticals About To Breakdown?  2021/04/20 13:41:50 Benzinga
There is a good chance Tonix Pharmaceuticals (NASDAQ: TNXP ) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically. Many investors like to place their orders at nice round levels and that’s the case here. When TNXP fell to $1 in early March, a rally followed. But that may … Full story available on Benzinga.com
   Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact  2021/04/19 11:52:04 Benzinga
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19. The financial details of the deal were … Full story available on Benzinga.com
   worth buying post Earnings results? NASDAQ:TNXP NASDAQ:CUE NASDAQ:SMTC NASDAQ:HHR and #Covid-19 (#Coronavirus) impact  2021/03/20 19:14:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia  2021/03/19 11:58:01 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. which is paid by Tonix Pharmaceuticals Holding Corp. to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) announced late last year positive results for the first of two pivotal Phase 3 studies of its lead fibromyalgia drug candidate, TNX-102 SL. The company reported that the results from its Phase 3 RELIEF study revealed TNX-102 SL provided statistically significant daily pain reduction over placebo while also being well-tolerated by participants in the study. “We are delighted with the results of our first positive Phase 3 study of TNX-102 SL for the management of fibromyalgia,” said Tonix Pharmaceuticals CEO, Dr. Seth Lederman. “RELIEF is the first of two studies that are required for approval by the U.S.
   NewtoTheStreet's Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin - Stocks News Feed  2021/02/13 20:39:00 Stocks News Feed
NEW YORK, NY / ACCESSWIRE / February 13, 2021 / New To The Street will broadcast Show 151 Sunday 930AM EST on NEWSMAX T.V., and on FOX Business Monday evening 1030PM PST. The show will feature Doctor Seth Lederman President and co-founder Tonix Pharma, a research driven biotechnology company. Tonix is working on a 1… Read More »NewtoTheStreet’s Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin

calendar